Premium
Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
Author(s) -
Masciullo Valeria,
Scambia Giovanni,
Marone Maria,
Giannitelli Cecilia,
Ferrandina Gabriella,
Bellacosa Alfonso,
Benedetti Panici Pierluigi,
Mancuso Salvatore
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970822)74:4<390::aid-ijc5>3.0.co;2-q
Subject(s) - cyclin d1 , gene , cancer research , biology , cyclin , gene expression , ovary , oncology , genetics , medicine , cell cycle
We analyzed the expression and amplification of cyclin D1 and CDK4 genes in ovarian carcinomas. Northern blot analysis revealed overexpression of cyclin D1 in 12 of 65 (18%) ovarian carcinomas while CDK4 was overexpressed in 7 of 48 cases (14%). None of the tumors showed amplification of any of the 2 genes. Overexpression of cyclin D1 and CDK4 transcripts was correlated, suggesting a role of both genes in altered growth control of ovarian cancer cells. Elevated levels of cyclin D1 were significantly associated with a well‐moderately differentiated grade (G1‐G2) ( p < 0.005). No significant association was found between cyclin D1 expression and estrogen receptor, progesterone and epidermal growth factor receptor content. Cyclin D1 expression does not appear to be associated with clinical outcome in human ovarian cancer, although a longer follow‐up period and screening of other molecules involved in the same pathway would be necessary to assess this hypothesis. Int. J. Cancer 74:390–395, 1997. © 1997 Wiley‐Liss, Inc.